Antiverse · News Wireframe
Announcement Series A closed at $9.3M · Research agreement with the Cystic Fibrosis Foundation →
Discuss your target Partnership options
News

What's happening.

Company announcements, partnership news, and coverage. A dedicated index — not a strip buried at the bottom of the homepage.

Page purpose — strategy §News and Blog. The current site's most recent dated content is from 2024, which signals abandonment rather than activity. Two fixes: (1) remove dates from news items now — common practice, and it solves the staleness problem immediately; (2) commit to a monthly cadence with a named owner. Do (1) today, build toward (2). This page implements (1) — no dates anywhere.
01Featured
Funding

Antiverse closes $9.3M Series A

Led by placeholder investor, with participation from existing backers. Capital directed at expanding the proprietary cell line library and advancing the wholly-owned pipeline.

Read the release →
Partnership

Research agreement with the Cystic Fibrosis Foundation

Applying generative antibody design to ion channel targets in cystic fibrosis — a class with zero approved antibodies to date.

Read the release →
02All news

Announcements

Partnership

Antiverse enters research collaboration with Top 15 Pharma partner

Placeholder — anonymised until sign-off is granted.

Read →
Coverage

Antiverse featured in The Times

Placeholder — national coverage of the platform and the funding round.

Read →
Programme

PAR1 program advances to lead optimisation

Placeholder — wholly-owned cardiovascular program milestone.

Read →
Company

Chuck Kunsch joins the Antiverse board

Former Managing Director, AbbVie Ventures.

Read →
Company

Antiverse opens Boston office

Placeholder — US presence to support North American partnerships.

Read →
Science

Placeholder — publication or preprint announcement

Links through to the publications list on the technology page.

Read →
No dates — deliberate. Items are tagged by type rather than stamped with a date. The moment a case study sign-off lands, it goes here within 24 hours, alongside a Murat/Ben LinkedIn post and a mail to the Tier 1 and Tier 2 lists. Speed of coordination signals an active, well-run company more than the content itself does.
03Media

As seen in

GEN Drug Target Review Manufacturing Chemist DDW The Times Axios Sifted
Media wall — strategy §Interim trust signals. Murat's byline articles curated as a visible wall. They exist already; they are simply not surfaced.

Get it monthly instead.

GPCR Intelligence — a curated briefing on the field, not a company newsletter.

Subscribe Read the insights